Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2017 03/24/2017 03/27/2017 03/28/2017 03/29/2017 Date
67.49(c) 67.51(c) 67.5(c) 67.1(c) 67.26(c) Last
6 174 908 6 037 791 5 455 289 8 509 127 7 224 725 Volume
-0.50% +0.03% -0.01% -0.59% +0.24% Change
More quotes
Financials ($)
Sales 2017 24 635 M
EBIT 2017 15 210 M
Net income 2017 10 403 M
Debt 2017 978 M
Yield 2017 3,18%
Sales 2018 22 710 M
EBIT 2018 13 475 M
Net income 2018 8 949 M
Debt 2018 1 343 M
Yield 2018 3,42%
P/E ratio 2017 9,16
P/E ratio 2018 9,94
EV / Sales2017 3,61x
EV / Sales2018 3,93x
Capitalization 87 925 M
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.Its primary areas of focus include primary areas of focus include human immunodeficiency virus, liver diseases such as chronic... 
More about the company
Surperformance© ratings of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES, INC.
03/28 HUMANITARIAN ORGANIZATIONS CHALLENGE : GILD) Sovaldi Patent
03/21 GILEAD SCIENCES : British Columbia lists EPCLUSA™ on public drug plan to t..
03/20 GILEAD SCIENCES : EPCLUSA™, to treat all six genotypes of chronic hepatiti..
03/14 GILEAD SCIENCES, INC. : ex-dividend day
03/09 GILEAD SCIENCES : to Present at the Barclays Global Healthcare Conference on Tue..
03/09 GILEAD SCIENCES : Reports on Medicinal Chemistry Findings from Gilead Sciences P..
03/07 Drugmaker shares slip as Trump tweets about pricing system
03/02 GILEAD SCIENCES : New Findings from Gilead Sciences Yields New Data on B-Cell Ly..
02/28 GILEAD SCIENCES : to Present at the Barclays Global Healthcare Conference on Tue..
02/27 GILEAD SCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
More news
Sector news : Bio Therapeutic Drugs
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES, INC. 
2014A valuable trading opportunity
2014Continuation of the bullish trend
More Strategies
Latest Tweets
04:59aGilead's Harvoni ads go from before to after with new creative focused on hep.. 
03/29Most Undervalued Stocks Of The S&P 500 - March 2017  
03/29Gilead's Harvoni ads go from before to after with new creative focused on hep..
2
03/29Peter was more audacious. He said the government should buy Gilead. But same ..
1
03/29Rahul Garg Says Trump's Tweets About Drug Prices Have Made Gilead A Buy: Forb..
1
More tweets
Qtime:301
News from SeekingAlpha
03/29 DIVGRO PULSE : March 2017
03/28 Most Undervalued Stocks Of The S&P 500 - March 2017
03/27 My Favorite Biotech Takeover Play
03/27 Will Trump Send Drug Stocks Tumbling Again?
03/27 Humanitarian groups still after Gilead's sofosbuvir patent
Advertisement
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 81,5 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-6.07%87 925
AMGEN, INC.11.52%120 086
CELGENE CORPORATION7.21%96 538
REGENERON PHARMACEUTIC..7.37%41 811
ACTELION LTD24.44%30 002
VERTEX PHARMACEUTICALS..46.61%26 834
More Results